Bain Capital Life Sciences Investors
Latest statistics and disclosures from Bain Capital Life Sciences Investors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Kailera Therapeutics, HTFL, NAMS, SVRA, ALKS, and represent 64.47% of Bain Capital Life Sciences Investors's stock portfolio.
- Added to shares of these 4 stocks: Kailera Therapeutics (+$498M), ALKS (+$70M), Hemab Therapeutics Holdings (+$61M), CABA (+$24M).
- Started 2 new stock positions in Kailera Therapeutics, Hemab Therapeutics Holdings.
- Reduced shares in these 8 stocks: NAMS (-$119M), HTFL (-$59M), Centessa Pharmaceuticals (-$25M), OLMA, ANNX, KYTX, UPB, AVIR.
- Sold out of its position in Centessa Pharmaceuticals.
- Bain Capital Life Sciences Investors was a net buyer of stock by $434M.
- Bain Capital Life Sciences Investors has $1.7B in assets under management (AUM), dropping by 51.70%.
- Central Index Key (CIK): 0001703031
Tip: Access up to 7 years of quarterly data
Positions held by Bain Capital Life Sciences Investors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 21 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Kailera Therapeutics Common Stock | 29.6 | $498M | NEW | 23M | 22.03 |
|
| Heartflow Inc/Sh (HTFL) | 14.7 | $248M | -19% | 8.4M | 29.34 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 7.7 | $129M | -47% | 3.8M | 33.89 |
|
| Savara (SVRA) | 6.4 | $108M | 18M | 6.16 |
|
|
| Alkermes SHS (ALKS) | 6.0 | $102M | +217% | 1.9M | 52.40 |
|
| Solid Biosciences Com New (SLDB) | 5.8 | $98M | 9.8M | 9.99 |
|
|
| Pharvaris N V (PHVS) | 5.5 | $93M | 2.7M | 34.58 |
|
|
| Olema Pharmaceuticals (OLMA) | 5.3 | $89M | -5% | 7.1M | 12.51 |
|
| Hemab Therapeutics Holdings Com Shs | 3.6 | $61M | NEW | 1.7M | 36.73 |
|
| Cabaletta Bio (CABA) | 3.2 | $54M | +78% | 17M | 3.11 |
|
| X4 Pharmaceuticals Com New (XFOR) | 2.2 | $37M | 8.0M | 4.67 |
|
|
| Dianthus Therapeutics (DNTH) | 2.1 | $35M | 363k | 97.48 |
|
|
| C4 Therapeutics Com Stk (CCCC) | 2.0 | $34M | 7.2M | 4.67 |
|
|
| Kyverna Therapeutics (KYTX) | 1.5 | $26M | -7% | 2.9M | 8.91 |
|
| Annexon (ANNX) | 1.5 | $25M | -14% | 4.4M | 5.71 |
|
| Rapid Micro Biosystems Class A Com (RPID) | 0.9 | $15M | 8.4M | 1.73 |
|
|
| Disc Medicine (IRON) | 0.6 | $10M | 141k | 73.14 |
|
|
| Atea Pharmaceuticals (AVIR) | 0.6 | $9.7M | -12% | 2.1M | 4.65 |
|
| Xilio Therapeutics (XLO) | 0.4 | $6.4M | 664k | 9.58 |
|
|
| Upstream Bio (UPB) | 0.2 | $4.2M | -30% | 601k | 6.92 |
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.1 | $2.1M | 100k | 21.37 |
|
Past Filings by Bain Capital Life Sciences Investors
SEC 13F filings are viewable for Bain Capital Life Sciences Investors going back to 2017
- Bain Capital Life Sciences Investors 2026 Q2 filed Aug. 14, 2026
- Bain Capital Life Sciences Investors 2026 Q1 filed May 15, 2026
- Bain Capital Life Sciences Investors 2025 Q4 filed Feb. 17, 2026
- Bain Capital Life Sciences Investors 2025 Q3 filed Nov. 14, 2025
- Bain Capital Life Sciences Investors 2025 Q2 filed Aug. 14, 2025
- Bain Capital Life Sciences Investors 2025 Q1 filed May 15, 2025
- Bain Capital Life Sciences Investors 2024 Q4 filed Feb. 14, 2025
- Bain Capital Life Sciences Investors 2024 Q3 filed Nov. 14, 2024
- Bain Capital Life Sciences Investors 2024 Q2 filed Aug. 12, 2024
- Bain Capital Life Sciences Investors 2024 Q1 filed May 15, 2024
- Bain Capital Life Sciences Investors 2023 Q3 filed Nov. 14, 2023
- Bain Capital Life Sciences Investors 2023 Q2 filed Aug. 14, 2023
- Bain Capital Life Sciences Investors 2023 Q1 filed May 15, 2023
- Bain Capital Life Sciences Investors 2022 Q4 filed Feb. 14, 2023
- Bain Capital Life Sciences Investors 2022 Q3 filed Nov. 14, 2022
- Bain Capital Life Sciences Investors 2022 Q2 filed Aug. 15, 2022